Skip to main content

CRON

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

CRON Price
Price Chart

Forward-looking statistics

Beta
0.97
Risk
45.59%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees406
Market cap$928.3M

Fundamentals

Enterprise value-$51.5M
Revenue$124.6M
Revenue per employee—
Profit margin39.69%
Debt to equity0.16

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.14
Dividend per share—
Revenue per share$0.33
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$2M
Put-call ratio—

Macro factor sensitivity

Growth+0.0
Credit+4.7
Liquidity+2.0
Inflation-4.6
Commodities-0.6
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio-51.00
Price to sales6.31
P/E Ratio-51.00
Enterprise Value to Revenue-0.41
Price to book0.74

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Cronos Q4 Sales Jump 27% On Higher Cannabis Flower And Extract Sales, Reports Improved Profitability

On Thursday, Cronos Group Inc CRON reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.

Benzinga (February 27, 2025)
Investing in Weed

Todd Harrison, founding partner and CIO at CB1 Capital Management, discusses marijuana investing and outlook for the industry on Bloomberg Markets. This interview aired 09/15/23

Bloomberg Markets and Finance (September 19, 2023)
Pot stocks rally after health officials ask DEA to reclassify marijuana as lower-risk drug

Assistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a schedule III substance.

Fox Business (August 30, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free